Ulrich Speck

TL;DR: Use of paclitaxel-coated angioplasty balloons during percutaneous treatment of femoropopliteal disease is associated with significant reductions in late lumen loss and target-lesion revascularization and no significant benefit is seen with the use of a paclitxel-containing contrast medium.

TL;DR: A randomized, double-blind, multicenter trial to compare the effects of a balloon catheter coated with paclitaxel (3 μg per square millimeter of balloon surface area) with those of an uncoated balloons catheter in coronary angioplasty found no significant differences.

TL;DR: Paclitaxel balloon coating caused no obvious adverse events and reduced restenosis in patients undergoing angioplasty of femoropopliteal arteries and the difference in target lesion revascularizations between treatment groups was maintained up to >18 months.

TL;DR: Paclitaxel balloon coating is safe, and it effectively inhibits restenosis after coronary angioplasty with stent implantation in the porcine model, and the degree of reduction in neointimal formation was comparable to that achieved with drug-eluting stents.

TL;DR: Treatment of coronary ISR with paclitaxel-coated balloon catheters persistently reduces repeat restenosis up to 2 years and after a complete follow-up of 2 years.